Prevention and Treatment of Tobacco Use: JACC Health Promotion Series

Journal of the American College of Cardiology

Volumn 72, Issue 9, 2018, Pages 1030-1045

  Kalkhoran, Sara ^a,b   Benowitz, Neal L ^c   Rigotti, Nancy A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

nicotine; smoking; smoking cessation; smoking prevention; tobacco use disorder

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE PATCH; NOSE SPRAY; TOBACCO SMOKE; VARENICLINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; EPIDEMIOLOGY; EVIDENCE BASED PRACTICE; HARM REDUCTION; HEALTH CARE PERSONNEL; HUMAN; LOZENGE; PASSIVE SMOKING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKELESS TOBACCO; SMOKING CESSATION; SMOKING PREVENTION; TOBACCO DEPENDENCE; TOBACCO USE; HEALTH PROMOTION; PREVENTION AND CONTROL;

HEALTH PROMOTION; HUMANS; TOBACCO USE; TOBACCO USE DISORDER;

EID: 85051125035     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.06.036     Document Type: Review

References (166)

1. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 389 (2017), 1885–1906.
2. Godtfredsen, N.S., Holst, C., Prescott, E., Vestbo, J., Osler, M., Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 156 (2002), 994–1001.
3. Jha, P., Ramasundarahettige, C., Landsman, V., et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368 (2013), 341–350.
4. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. 2014, Centers for Disease Control and Prevention, Atlanta, GA, 17.
5. World Health Organization. Tobacco. Available at: http://www.who.int/mediacentre/factsheets/fs339/en/. Accessed March 6, 2018.
6. Phillips, E., Wang, T.W., Husten, C.G., et al. Tobacco product use among adults—United States, 2015. MMWR Morb Mortal Wkly Rep 66 (2017), 1209–1215.
7. Jamal, A., Phillips, E., Gentzke, A.S., et al. Current cigarette smoking among adults—United States, 2016. MMWR Morb Mortal Wkly Rep 67 (2018), 53–59.
8. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The NSDUH report: adults with mental illness or substance use disorder account for 40 percent of all cigarettes smoked. Available at: https://www.samhsa.gov/data/sites/default/files/spot104-cigarettes-mental-illness-substance-use-disorder/spot104-cigarettes-mental-illness-substance-use-disorder.pdf. Accessed May 19, 2017.
9. Jamal, A., Gentzke, A., Hu, S.S., et al. Tobacco use among middle and high school students—United States, 2011–2016. MMWR Morb Mortal Wkly Rep 66 (2017), 597–603.
10. Kasza, K.A., Ambrose, B.K., Conway, K.P., et al. Tobacco-product use by adults and youths in the United States in 2013 and 2014. N Engl J Med 376 (2017), 342–353.
11. Tabuchi, T., Kiyohara, K., Hoshino, T., Bekki, K., Inaba, Y., Kunugita, N., Awareness and use of electronic cigarettes and heat-not-burn tobacco products in Japan. Addiction 111 (2016), 706–713.
12. Yusuf, S., Hawken, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
13. Thun, M.J., Carter, B.D., Feskanich, D., et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 368 (2013), 351–364.
14. Goldenberg, I., Jonas, M., Tenenbaum, A., et al. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 163 (2003), 2301–2305.
15. Hackshaw, A., Morris, J.K., Boniface, S., Tang, J.L., Milenkovic, D., Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ, 360, 2018, j5855.
16. Green, M.S., Jucha, E., Luz, Y., Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J 111 (1986), 932–940.
17. Primatesta, P., Falaschetti, E., Gupta, S., Marmot, M.G., Poulter, N.R., Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 37 (2001), 187–193.
18. Carter, B.D., Abnet, C.C., Feskanich, D., et al. Smoking and mortality—beyond established causes. N Engl J Med 372 (2015), 631–640.
19. Regalado, M., Yang, S., Wesson, D.E., Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 35 (2000), 687–694.
20. Lu, L., Mackay, D.F., Pell, J.P., Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart 100 (2014), 414–423.
21. Tomiyama, H., Hashimoto, H., Tanaka, H., et al. Continuous smoking and progression of arterial stiffening: a prospective study. J Am Coll Cardiol 55 (2010), 1979–1987.
22. Duval, S., Long, K.H., Roy, S.S., et al. The contribution of tobacco use to high health care utilization and medical costs in peripheral artery disease: a state-based cohort analysis. J Am Coll Cardiol 66 (2015), 1566–1574.
23. Lederle, F.A., Johnson, G.R., Wilson, S.E., et al. The aneurysm detection and management study screening program: validation cohort and final results. Arch Intern Med 160 (2000), 1425–1430.
24. Sweeting, M.J., Thompson, S.G., Brown, L.C., Powell, J.T., Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 99 (2012), 655–665.
25. Chamberlain, A.M., Agarwal, S.K., Folsom, A.R., et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 8 (2011), 1160–1166.
26. Goldenberg, I., Moss, A.J., McNitt, S., et al. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 17 (2006), 931–936.
27. Gopal, D.M., Kalogeropoulos, A.P., Georgiopoulou, V.V., et al. Cigarette smoking exposure and heart failure risk in older adults: the Health, Aging, and Body Composition Study. Am Heart J 164 (2012), 236–242.
28. Suskin, N., Sheth, T., Negassa, A., Yusuf, S., Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 37 (2001), 1677–1682.
29. Rea, T.D., Heckbert, S.R., Kaplan, R.C., Smith, N.L., Lemaitre, R.N., Psaty, B.M., Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 137 (2002), 494–500.
30. Epstein, K.A., Viscoli, C.M., Spence, J.D., et al. Smoking cessation and outcome after ischemic stroke or TIA. Neurology 89 (2017), 1723–1729.
31. van Domburg, R.T., Meeter, K., van Berkel, D.F., Veldkamp, R.F., van Herwerden, L.A., Bogers, A.J., Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol 36 (2000), 878–883.
32. Hasdai, D., Garratt, K.N., Grill, D.E., Lerman, A., Holmes, D.R. Jr., Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 336 (1997), 755–761.
33. Barnoya, J., Glantz, S.A., Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 111 (2005), 2684–2698.
34. Oono, I.P., Mackay, D.F., Pell, J.P., Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf) 33 (2011), 496–502.
35. National Cancer Institute and Centers for Disease Control and Prevention. Smokeless Tobacco and Public Health: A Global Perspective. NIH Publication No. 14-7983. 2014, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Institutes of Health, National Cancer Institute, Bethesda, Maryland.
36. Piano, M.R., Benowitz, N.L., Fitzgerald, G.A., et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation 122 (2010), 1520–1544.
37. Boffetta, P., Straif, K., Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ, 339, 2009, b3060.
38. Arefalk, G., Hambraeus, K., Lind, L., Michaelsson, K., Lindahl, B., Sundstrom, J., Discontinuation of smokeless tobacco and mortality risk after myocardial infarction. Circulation 130 (2014), 325–332.
39. Teo, K.K., Ounpuu, S., Hawken, S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368 (2006), 647–658.
40. Messner, B., Bernhard, D., Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 34 (2014), 509–515.
41. Brook, R.D., Rajagopalan, S., Pope, C.A. 3rd, et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 121 (2010), 2331–2378.
42. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. 2006, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, 709.
43. Hecht, S.S., Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91 (1999), 1194–1210.
44. Benowitz, N.L., Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 46 (2003), 91–111.
45. Saleheen, D., Zhao, W., Young, R., et al. Loss of cardioprotective effects at the ADAMTS7 locus as a result of gene-smoking interactions. Circulation 135 (2017), 2336–2353.
46. Bonnie, R.J., Kwan, L.Y., Stratton, K.R., (eds.) Public health implications of raising the minimum age of legal access to tobacco products, 2015, National Academies Press, Washington, DC.
47. U.S. Department of Health Human Services. Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. 2012, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, 3.
48. Hughes, J.R., Solomon, L.J., Naud, S., Fingar, J.R., Helzer, J.E., Callas, P.W., Natural history of attempts to stop smoking. Nicotine Tob Res 16 (2014), 1190–1198.
49. Chaiton, M., Diemert, L., Cohen, J.E., et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open, 6, 2016.
50. Babb, S., Malarcher, A., Schauer, G., Asman, K., Jamal, A., Quitting smoking among adults—United States, 2000–2015. MMWR Morb Mortal Wkly Rep 65 (2017), 1457–1464.
51. Fiore, M.C., Bailey, W.C., Cohen, S.J., et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. 2000, US Department of Health and Human Services, Rockville, MD 00–0032.
52. DiFranza, J., Savageau, J., Rigotti, N., et al. Development of symptoms of tobacco dependence in youths: 30 month follow up data from the DANDY study. Tob Control 11 (2002), 228–235.
53. Doubeni, C.A., Reed, G., Difranza, J.R., Early course of nicotine dependence in adolescent smokers. Pediatrics 125 (2010), 1127–1133.
54. Hughes, J.R., Hatsukami, D., Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 (1986), 289–294.
55. Herd, N., Borland, R., The natural history of quitting smoking: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction (Abingdon, England) 104 (2009), 2075–2087.
56. McLeroy, K.R., Bibeau, D., Steckler, A., Glanz, K., An ecological perspective on health promotion programs. Health Educ Q 15 (1988), 351–377.
57. Tyas, S.L., Pederson, L.L., Psychosocial factors related to adolescent smoking: a critical review of the literature. Tobacco Control 7 (1998), 409–420.
58. Chaiton, M.O., Cohen, J.E., O'Loughlin, J., Rehm, J., A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC Public Health, 9, 2009, 356.
59. Patton, G.C., Carlin, J.B., Coffey, C., Wolfe, R., Hibbert, M., Bowes, G., Depression, anxiety, and smoking initiation: a prospective study over 3 years. Am J Public Health 88 (1998), 1518–1522.
60. Vink, J.M., Willemsen, G., Boomsma, D.I., Heritability of smoking initiation and nicotine dependence. Behav Genet 35 (2005), 397–406.
61. Kobus, K., Peers and adolescent smoking. Addiction 98 Suppl 1 (2003), 37–55.
62. Ellickson, P.L., Bird, C.E., Orlando, M., Klein, D.J., McCaffrey, D.F., Social context and adolescent health behavior: does school-level smoking prevalence affect students’ subsequent smoking behavior?. J Health Soc Behav 44 (2003), 525–535.
63. Chaloupka, F.J., Macro-social influences: the effects of prices and tobacco-control policies on the demand for tobacco products. Nicotine Tob Res 1 Suppl 1 (1999), S105–S109.
64. Ross, H., Chaloupka, F.J., The effect of cigarette prices on youth smoking. Health Econ 12 (2003), 217–230.
65. Chaloupka, F.J., Wechsler, H., Price, tobacco control policies and smoking among young adults. J Health Econ 16 (1997), 359–373.
66. Wellman, R.J., Sugarman, D.B., DiFranza, J.R., Winickoff, J.P., The extent to which tobacco marketing and tobacco use in films contribute to children's use of tobacco: a meta-analysis. Arch Pediatr Adolesc Med 160 (2006), 1285–1296.
67. Pierce, J.P., Choi, W.S., Gilpin, E.A., Farkas, A.J., Berry, C.C., Tobacco industry promotion of cigarettes and adolescent smoking. JAMA 279 (1998), 511–515.
68. Song, A.V., Dutra, L.M., Neilands, T.B., Glantz, S.A., Association of smoke-free laws with lower percentages of new and current smokers among adolescents and young adults: an 11-year longitudinal study. JAMA Pediatr, 169, 2015, e152285.
69. Cheng, K.W., Okechukwu, C.A., McMillen, R., Glantz, S.A., Association between clean indoor air laws and voluntary smokefree rules in homes and cars. Tob Control 24 (2015), 168–174.
70. Farkas, A.J., Gilpin, E.A., White, M.M., Pierce, J.P., Association between household and workplace smoking restrictions and adolescent smoking. JAMA 284 (2000), 717–722.
71. Stead, L.F., Lancaster, T., Interventions for preventing tobacco sales to minors. Cochrane Database Syst Rev, 2005, Cd001497.
72. Dai, H., Hao, J., Temporal trends of sources of cigarettes among U.S. high school students: 2001–2015. Nicotine Tob Res, 2018 Jan 12 [E-pub ahead of print].
73. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. 2010, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, 2.
74. Goodwin, R.D., Pagura, J., Spiwak, R., Lemeshow, A., Sareen, J., Predictors of persistent nicotine dependence among adults in the United States. Drug Alcohol Depend 118 (2011), 127–133.
75. Farkas, A.J., Gilpin, E.A., Distefan, J.M., Pierce, J.P., The effects of household and workplace smoking restrictions on quitting behaviours. Tob Control 8 (1999), 261–265.
76. Christakis, N.A., Fowler, J.H., Quitting in droves: collective dynamics of smoking behavior in a large social network. N Engl J Med 358 (2008), 2249–2258.
77. Hitchman, S.C., Fong, G.T., Zanna, M.P., Thrasher, J.F., Laux, F.L., The relation between number of smoking friends, and quit intentions, attempts, and success: findings from the International Tobacco Control (ITC) Four Country Survey. Psychol Addict Behav 28 (2014), 1144–1152.
78. Mermelstein, R., Cohen, S., Lichtenstein, E., Baer, J.S., Kamarck, T., Social support and smoking cessation and maintenance. J Consult Clin Psychol 54 (1986), 447–453.
79. Bauer, J.E., Hyland, A., Li, Q., Steger, C., Cummings, K.M., A longitudinal assessment of the impact of smoke-free worksite policies on tobacco use. Am J Public Health 95 (2005), 1024–1029.
80. Mayne, S.L., Auchincloss, A.H., Stehr, M.F., et al. Longitudinal associations of local cigarette prices and smoking bans with smoking behavior in the Multi-Ethnic Study of Atherosclerosis. Epidemiology 28 (2017), 863–871.
81. Chaloupka, F.J., Straif, K., Leon, M.E., Effectiveness of tax and price policies in tobacco control. Tob Control 20 (2011), 235–238.
82. Bala, M.M., Strzeszynski, L., Topor-Madry, R., Mass media interventions for smoking cessation in adults. Cochrane Database Syst Rev, 11, 2017, Cd004704.
83. Nash, S.H., Liao, L.M., Harris, T.B., Freedman, N.D., Cigarette smoking and mortality in adults aged 70 years and older: results from the NIH-AARP cohort. Am J Prev Med 52 (2017), 276–283.
84. U.S. Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. 2004, Centers for Disease Control and Prevention, Atlanta, GA.
85. Benowitz, N.L., Fitzgerald, G.A., Wilson, M., Zhang, Q., Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 22 (1993), 1159–1167.
86. Peto, R., Darby, S., Deo, H., Silcocks, P., Whitley, E., Doll, R., Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321 (2000), 323–329.
87. Critchley, J.A., Capewell, S., Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 290 (2003), 86–97.
88. Wilson, K., Gibson, N., Willan, A., Cook, D., Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 160 (2000), 939–944.
89. Buchanan, D.M., Arnold, S.V., Gosch, K.L., et al. Association of smoking status with angina and health-related quality of life after acute myocardial infarction. Circ Cardiovasc Qual Outcomes 8 (2015), 493–500.
90. Anthonisen, N.R., Connett, J.E., Kiley, J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (1994), 1497–1505.
91. Kanner, R.E., Connett, J.E., Williams, D.E., Buist, A.S., Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 106 (1999), 410–416.
92. Au, D.H., Bryson, C.L., Chien, J.W., et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med 24 (2009), 457–463.
93. Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E., Connett, J.E., The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005), 233–239.
94. Parsons, A., Daley, A., Begh, R., Aveyard, P., Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ, 340, 2010, b5569.
95. Begh, R., Lindson-Hawley, N., Aveyard, P., Does reduced smoking if you can't stop make any difference?. BMC Med, 13, 2015, 257.
96. Tverdal, A., Bjartveit, K., Health consequences of reduced daily cigarette consumption. Tob Control 15 (2006), 472–480.
97. Tan, C.E., Glantz, S.A., Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis. Circulation 126 (2012), 2177–2183.
98. Been, J.V., Nurmatov, U.B., Cox, B., Nawrot, T.S., van Schayck, C.P., Sheikh, A., Effect of smoke-free legislation on perinatal and child health: a systematic review and meta-analysis. Lancet 383 (2014), 1549–1560.
99. World Health Organization. WHO Framework Convention on Tobacco Control. 2003, World Health Organization, Geneva.
100. Drope, J., Schluger, N., Cahn, Z., et al. The Tobacco Atlas. 2018, American Cancer Society and Vital Strategies, Atlanta.
101. World Health Organization. WHO Report on the Global Tobacco Epidemic 2017: Monitoring Tobacco Use and Prevention Policies. 2017, World Health Organization, Geneva.
102. Hiilamo, H., Glantz, S., FCTC followed by accelerated implementation of tobacco advertising bans. Tob Control 26 (2017), 428–433.
103. Uang, R., Hiilamo, H., Glantz, S.A., Accelerated adoption of smoke-free laws after ratification of the World Health Organization framework convention on tobacco control. Am J Public Health 106 (2016), 166–171.
104. Gravely, S., Giovino, G.A., Craig, L., et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. The Lancet Public Health 2 (2017), e166–e174.
105. Gottlieb, S., Zeller, M., A nicotine-focused framework for public health. N Engl J Med 377 (2017), 1111–1114.
106. Benowitz, N.L., Donny, E.C., Hatsukami, D.K., Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. Addiction 112 (2017), 6–7.
107. Donny, E.C., Denlinger, R.L., Tidey, J.W., et al. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med 373 (2015), 1340–1349.
108. Hatsukami, D.K., Kotlyar, M., Hertsgaard, L.A., et al. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 105 (2010), 343–355.
109. Hatsukami, D.K., Donny, E.C., Koopmeiners, J.S., Benowitz, N.L., Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24 (2015), 472–476.
110. Hatsukami, D.K., Luo, X., Dick, L., et al. Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial. Addiction 112 (2017), 156–167.
111. Apelberg, B.J., Feirman, S.P., Salazar, E., et al. Potential public health effects of reducing nicotine levels in cigarettes in the United States. N Engl J Med 378 (2018), 1725–1733.
112. Fairchild, A.L., Lee, J.S., Bayer, R., Curran, J., E-cigarettes and the harm-reduction continuum. N Engl J Med 378 (2018), 216–219.
113. National Academies of Sciences Engineering and Medicine. Public health consequences of e-cigarettes. 2018, The National Academies Press, Washington, DC.
114. Jamal, A., Dube, S.R., King, B.A., Tobacco use screening and counseling during hospital outpatient visits among US adults, 2005–2010. Prev Chronic Dis, 12, 2015, E132.
115. Stead, L.F., Buitrago, D., Preciado, N., Sanchez, G., Hartmann-Boyce, J., Lancaster, T., Physician advice for smoking cessation. Cochrane Database Syst Rev, 2013, Cd000165.
116. Barth, J., Jacob, T., Daha, I., Critchley, J.A., Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev, 2015, Cd006886.
117. Rigotti, N.A., Clair, C., Munafo, M.R., Stead, L.F., Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev, 2012, Cd001837.
118. Pagidipati, N.J., Hellkamp, A., Thomas, L., Gulati, M., Peterson, E.D., Wang, T.Y., Use of prescription smoking cessation medications after myocardial infarction among older patients in community practice. JAMA Cardiol 2 (2017), 1040–1042.
119. Stead, L.F., Lancaster, T., Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev, 10, 2012, Cd008286.
120. Fiore, M.C., Jaen, C.R., Baker, T., et al. Treating tobacco use and dependence: 2008 update. 2008, U.S. Department of Health and Human Services, Rockville, MD.
121. Winickoff, J.P., Hipple, B., Drehmer, J., et al. The Clinical Effort Against Secondhand Smoke Exposure (CEASE) Intervention: a decade of lessons learned. J Clin Outcomes Manag 19 (2012), 414–419.
122. Lancaster, T., Stead, L.F., Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev, 3, 2017, Cd001292.
123. Stead, L.F., Carroll, A.J., Lancaster, T., Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev, 3, 2017, Cd001007.
124. Stead, L.F., Hartmann-Boyce, J., Perera, R., Lancaster, T., Telephone counselling for smoking cessation. Cochrane Database Syst Rev, 2013, Cd002850.
125. Whittaker, R., McRobbie, H., Bullen, C., Rodgers, A., Gu, Y., Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev, 4, 2016, Cd006611.
126. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. SmokefreeTXT. Available at: http://smokefree.gov/smokefreetxt. Accessed July 5, 2018.
127. White, A.R., Rampes, H., Liu, J.P., Stead, L.F., Campbell, J., Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev, 1, 2014, Cd000009.
128. Barnes, J., Dong, C.Y., McRobbie, H., Walker, N., Mehta, M., Stead, L.F., Hypnotherapy for smoking cessation. Cochrane Database Syst Rev, 2010, Cd001008.
129. Stead, L.F., Perera, R., Bullen, C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 11, 2012, Cd000146.
130. Mills, E.J., Thorlund, K., Eapen, S., Wu, P., Prochaska, J.J., Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 129 (2014), 28–41.
131. Joseph, A.M., Norman, S.M., Ferry, L.H., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335 (1996), 1792–1798.
132. Cahill, K., Stead, L.F., Lancaster, T., Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 4, 2012, Cd006103.
133. Anthenelli, R.M., Benowitz, N.L., West, R., et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387 (2016), 2507–2520.
134. Rigotti, N.A., Pipe, A.L., Benowitz, N.L., Arteaga, C., Garza, D., Tonstad, S., Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121 (2010), 221–229.
135. Eisenberg, M.J., Windle, S.B., Roy, N., et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation 133 (2016), 21–30.
136. Windle, S.B., Dehghani, P., Roy, N., et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ 190 (2018), E347–E354.
137. Benowitz, N.L., Pipe, A., West, R., et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med 178 (2018), 622–631.
138. Singh, S., Loke, Y.K., Spangler, J.G., Furberg, C.D., Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 183 (2011), 1359–1366.
139. Ware, J.H., Vetrovec, G.W., Miller, A.B., et al. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. Am J Ther 20 (2013), 235–246.
140. Sterling, L.H., Windle, S.B., Filion, K.B., Touma, L., Eisenberg, M.J., Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 5, 2016, e002849.
141. Prochaska, J.J., Hilton, J.F., Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ, 344, 2012, e2856.
142. Kotz, D., Viechtbauer, W., Simpson, C., van Schayck, O.C., West, R., Sheikh, A., Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 3 (2015), 761–768.
143. Monárrez-Espino, J., Galanti, M.R., Hansson, J., Janszky, I., Söderberg-Löfdal, K., Möller, J., Treatment with bupropion and varenicline for smoking cessation and the risk of acute cardiovascular events and injuries: a Swedish case-crossover study. Nicotine Tob Res 20 (2018), 606–613.
144. Svanstrom, H., Pasternak, B., Hviid, A., Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ, 345, 2012, e7176.
145. Gershon, A.S., Campitelli, M.A., Hawken, S., et al. Cardiovascular and neuropsychiatric events following varenicline use for smoking cessation. Am J Respir Crit Care Med 197 (2018), 913–922.
146. Kalhan, R., Wilkins, J.T., Hitsman, B.L., Tobacco smoking is a medical problem: we ought to treat it like one. Am J Respir Crit Care Med 197 (2018), 852–853.
147. Cahill, K., Lindson-Hawley, N., Thomas, K.H., Fanshawe, T.R., Lancaster, T., Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2016, Cd006103.
148. Hughes, J.R., Stead, L.F., Hartmann-Boyce, J., Cahill, K., Lancaster, T., Antidepressants for smoking cessation. Cochrane Database Syst Rev, 1, 2014, Cd000031.
149. Eisenberg, M.J., Grandi, S.M., Gervais, A., et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 61 (2013), 524–532.
150. Planer, D., Lev, I., Elitzur, Y., et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 171 (2011), 1055–1060.
151. Czernin, J., Waldherr, C., Cigarette smoking and coronary blood flow. Prog Cardiovasc Dis 45 (2003), 395–404.
152. Ambrose, J.A., Barua, R.S., The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43 (2004), 1731–1737.
153. Simpson, A.J., Gray, R.S., Moore, N.R., Booth, N.A., The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol 97 (1997), 208–213.
154. Newby, D.E., McLeod, A.L., Uren, N.G., et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 103 (2001), 1936–1941.
155. Matetzky, S., Tani, S., Kangavari, S., et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 102 (2000), 602–604.
156. Lehr, H.A., Frei, B., Arfors, K.E., Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci U S A 91 (1994), 7688–7692.
157. Levitzky, Y.S., Guo, C.Y., Rong, J., et al. Relation of smoking status to a panel of inflammatory markers: the Framingham offspring. Atherosclerosis 201 (2008), 217–224.
158. Barbieri, S.S., Zacchi, E., Amadio, P., et al. Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res 90 (2011), 475–483.
159. McEvoy, J.W., Nasir, K., DeFilippis, A.P., et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 35 (2015), 1002–1010.
160. Craig, W.Y., Palomaki, G.E., Haddow, J.E., Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 298 (1989), 784–788.
161. Grundy, S.M., Oxidized LDL and atherogenesis: relation to risk factors for coronary heart disease. Clin Cardiol 16 (1993), I3–I5.
162. Goette, A., Lendeckel, U., Kuchenbecker, A., et al. Cigarette smoking induces atrial fibrosis in humans via nicotine. Heart 93 (2007), 1056–1063.
163. Willi, C., Bodenmann, P., Ghali, W.A., Faris, P.D., Cornuz, J., Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298 (2007), 2654–2664.
164. Facchini, F.S., Hollenbeck, C.B., Jeppesen, J., Chen, Y.D., Reaven, G.M., Insulin resistance and cigarette smoking. Lancet 339 (1992), 1128–1130.
165. Wu, Y., Song, P., Zhang, W., et al. Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat Med 21 (2015), 373–382.
166. Sugiishi, M., Takatsu, F., Cigarette smoking is a major risk factor for coronary spasm. Circulation 87 (1993), 76–79.